Bavarian Nordic Receives USD 22.5 Million Contract for its Mpox and Smallpox Vaccine from the Government of Canada

Core Insights - Bavarian Nordic A/S has secured a new order worth USD 22.5 million from the Public Health Agency of Canada for its mpox and smallpox vaccine, MVA-BN, under a 10-year contract established in 2022 [1][6] - The company has achieved approximately DKK 1,400 million in orders for its Public Preparedness business in 2026, reflecting an increase of DKK 100 million compared to previous communications, with full-year guidance remaining at DKK 1,800-2,000 million [2] - The CEO of Bavarian Nordic emphasized the importance of public preparedness in Canada and the company's commitment to supporting government efforts against health threats like mpox and smallpox, highlighting collaborations with the US and EU [3] Company Overview - Bavarian Nordic is a global vaccine company focused on improving health through innovative vaccines, serving as a preferred supplier of mpox and smallpox vaccines to governments [5] - The MVA-BN vaccine is the only non-replicating mpox vaccine approved in multiple regions, including the U.S., Canada, and the EU, originally developed to ensure smallpox vaccination for the entire population, including immunocompromised individuals [4]